Brief: Sellas Life Sciences Receives Favorable FDA Type C Meeting Feedback On CMC Biologics License Application (BLA)
13/11/2023 14:43
Nov 13 (Reuters) - Sellas Life Sciences Group Inc
SLS.O :
* SELLAS LIFE SCIENCES RECEIVES FAVORABLE FDA TYPE C MEETING
FEEDBACK ON CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC)
BIOLOGICS LICENSE APPLICATION (BLA) FILING STRATEGY FOR
GALINPEPIMUT-S (GPS)
Source text for Eikon: ID:nGNX7ZHXtl
Further company coverage: SLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses